

Jori Symons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/746472/publications.pdf>

Version: 2024-02-01

15
papers

487
citations

687363

13
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

991
citing authors

#	ARTICLE	IF	CITATIONS
1	In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab553.	0.9	4
2	<i>In Vivo</i> T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design. <i>ACS Nano</i> , 2021, 15, 3736-3753.	14.6	50
3	Acoustofection: High-Frequency Vibrational Membrane Permeabilization for Intracellular siRNA Delivery into Nonadherent Cells. <i>ACS Applied Bio Materials</i> , 2021, 4, 2781-2789.	4.6	23
4	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. <i>PLoS Pathogens</i> , 2021, 17, e1009214.	4.7	25
5	CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 ⁺ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. <i>Journal of Virology</i> , 2020, 94, .	3.4	18
6	HIV integration sites in latently infected cell lines: evidence of ongoing replication. <i>Retrovirology</i> , 2017, 14, 2.	2.0	59
7	Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0132430.	2.5	26
8	Dependence on the CCR5 Coreceptor for Viral Replication Explains the Lack of Rebound of CXCR4-Predicted HIV Variants in the Berlin Patient. <i>Clinical Infectious Diseases</i> , 2014, 59, 596-600.	5.8	35
9	Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2007-2014.	3.0	8
10	HIV population genotypic tropism testing and its clinical significance. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 470-477.	3.8	30
11	Efficacy and safety of an attenuated live QX-like infectious bronchitis virus strain as a vaccine for chickens. <i>Avian Pathology</i> , 2011, 40, 93-102.	2.0	32
12	Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 890-895.	3.0	30
13	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2010, 201, 1054-1062.	4.0	27
14	HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 51, 620-628.	5.8	26
15	Functional Constraints of Influenza A Virus Epitopes Limit Escape from Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2005, 79, 11239-11246.	3.4	89